Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Reactive Oxygen Species (ROS)-Based Nanomedicine.
Bowen Yang,Yu Chen,Jianlin Shi +2 more
TL;DR: In this article, the intrinsic biochemical properties of reactive oxygen species (ROS) underlie the mechanisms that regulate various physiological functions of living organisms, and they play an essential role in regulating various physiological function.
Journal ArticleDOI
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Marta Seretny,Gillian L. Currie,Emily S. Sena,Sabrina Ramnarine,Robin Grant,Malcolm R. Macleod,Leslie A. Colvin,Marie Fallon +7 more
TL;DR: A systematic review of studies reporting the prevalence of Chemotherapy‐induced peripheral neuropathy identified 31 studies with data from 4179 patients and identified a number of genetic and clinical risk factors that require further study.
Journal ArticleDOI
Microbiota: a key orchestrator of cancer therapy.
Soumen Roy,Giorgio Trinchieri +1 more
TL;DR: The evidence for the ability of the microbiota to modulate chemotherapy, radiotherapy and immunotherapy is discussed with a focus on the microbial species involved, their mechanism of action and the possibility of targeting the microbiome to improve anticancer efficacy while preventing toxicity.
Journal ArticleDOI
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.
Renata Zajączkowska,Magdalena Kocot-Kępska,Wojciech Leppert,Anna Wrzosek,Joanna Mika,Jerzy Wordliczek +5 more
TL;DR: A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies and the neurotoxicity mechanisms of the most common antineoplastic agents are reviewed.
Journal ArticleDOI
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova,Irina Vetter +1 more
TL;DR: This review focusses on the commonly used antineoplastic substances oxaliplatin, cisPlatin, vincristine, docetaxel, and paclitaxel which interfere with the cancer cell cycle—leading to cell death and tumor degradation—and cause severe acute and chronic peripheral neuropathies.
References
More filters
Journal ArticleDOI
Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current
Ruth Sittl,Angelika Lampert,Tobias Huth,E. Theresa Schuy,Andrea S. Link,Johannes Fleckenstein,Christian Alzheimer,Peter Grafe,Richard W. Carr +8 more
TL;DR: This work suggests that NaV1.6 plays a central role in mediating acute cooling-exacerbated symptoms following oxaliplatin, and that enhanced resurgent and persistent sodium currents may provide a general mechanistic basis for cold-aggravated symptoms of neuropathy.
Journal ArticleDOI
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
Mace L. Rothenberg,John Cox,Charles Butts,M. Navarro,Yung-Jue Bang,Rakesh Goel,Simon Gollins,L.L. Siu,S. Laguerre,David Cunningham +9 more
TL;DR: XELOX is noninferior to FOLFOX-4 when administered as second-line treatment in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy.
Journal ArticleDOI
Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients
Wei Shu Wang,Jen Kou Lin,Jen Kou Lin,Tzu Chen Lin,Tzu Chen Lin,Wei Shone Chen,Wei Shone Chen,Jeng Kae Jiang,Jeng Kae Jiang,Huann Sheng Wang,Huann Sheng Wang,Tzeon Jye Chiou,Tzeon Jye Chiou,Jin Hwang Liu,Jin Hwang Liu,Chueh Chuan Yen,Chueh Chuan Yen,Po Min Chen,Po Min Chen +18 more
TL;DR: It is shown that oral glutamine significantly reduces the incidence and severity of peripheral neuropathy of MCRC patients receiving oxaliplatin without affecting response to chemotherapy and survival.
Journal ArticleDOI
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
Craig B. Reeder,Donna E. Reece,Vishal Kukreti,Christine Chen,Suzanne Trudel,Kristina Laumann,Joseph G. Hentz,Nicholas A. Pirooz,Jesus Giovanni Piza,Rodger E. Tiedemann,Joseph R. Mikhael,Peter Leif Bergsagel,Jose F. Leis,Rafael Fonseca,Alexander Keith Stewart +14 more
TL;DR: A 3-drug combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD) in newly diagnosed symptomatic patients in relapsed multiple myeloma patients was examined.
Journal ArticleDOI
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
Axel Grothey,Daniel A. Nikcevich,Jeff A. Sloan,John W. Kugler,Peter T. Silberstein,Todor Dentchev,Donald B. Wender,Paul J. Novotny,Umesh Chitaley,Steven R. Alberts,Charles L. Loprinzi +10 more
TL;DR: IV Ca/Mg is supported as an effective neuroprotectant against oxaliplatin-induced cumulative sNT in adjuvant colon cancer in a nonrandomized, retrospective study.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more